FilingReader Intelligence
HBM Holdings to present cancer drug data at ESMO
July 30, 2025 at 12:13 AM UTC•By FilingReader AI
HBM Holdings will present Phase II data for HBM4003 combined with tislelizumab in metastatic colorectal cancer at the European Society for Medical Oncology Congress 2025 in Berlin, October 17-21.
The presentation will cover efficacy and safety results from a multicenter Phase II study of the anti-CTLA-4 antibody combination treatment.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2142•Hong Kong Exchange
News Alerts
Get instant email alerts when HBM Holdings publishes news
Free account required • Unsubscribe anytime